

Curriculum Vitae of
William J. Millard

Addresses:

Home: 6724 NW 24th Place
Gainesville, FL 32606.
(352) 338-0110.

Departmental: Department of Pharmacodynamics
Box 100487, J. Hillis Miller Health Center
College of Pharmacy
University of Florida
Gainesville, FL 32610-0487.
(352) 846-1345; (352) 392-3408 *Fax:* (352) 392-9187

Dean's Office: Box 100484, J. Hillis Miller Health Center
College of Pharmacy
University of Florida
Gainesville, FL 32610-0484.
(352) 273-6311 *Fax:* (352) 273-6306

E-mail address: millard@cop.ufl.edu

World Wide Web: <http://www.cop.ufl.edu/departments/PD/faculty/millard/index.htm>

Date of Birth: August 6, 1949.

Place of Birth: Yakima, Washington.

Marital Status: Married. wife, Beverly: sons, Jason and Justin.

Education:

1971 B.S. Mount Union College. Alliance, Ohio.
1979 Ph.D. (Biology) University of Toledo. Toledo, Ohio.

Postdoctoral Training:

1979-1981 Research Fellow in Neurology, Massachusetts General Hospital. Boston, MA 02114.
1981-1982 Research Associate in Neuroscience, Department of Neuroscience, Children's Hospital Medical Center. Boston, MA 02115.
1981-1982 Research Associate in Neurology, Department of Neurology, Massachusetts General Hospital. Boston, MA 02114.

Academic Appointments:

1972-1973, 1975-1976 Graduate Assistant, University of Toledo.
1982-1983 Instructor in Neurology, Harvard Medical School. Boston, MA 02115.
1983-1986 Assistant Professor of Physiology (Neurology), Harvard Medical School. Boston, MA 02115.
1986-1997 Associate Professor of Pharmacy, Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610-0487.
1997- Professor of Pharmacy, Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610-0487.

Administrative Appointments:

1995-1997	Acting Associate Dean for Research and Graduate Studies, College of Pharmacy, University of Florida, Gainesville, FL 32610-0484.
1997-1998	Associate Dean for Research and Graduate Studies, College of Pharmacy, University of Florida, Gainesville, FL 32610-0484.
1999-	Executive Associate Dean, College of Pharmacy, University of Florida, Gainesville, FL 32610-0484.

Hospital Appointments:

1982-1986 02114.	Assistant in Neuroendocrinology, Massachusetts General Hospital, Boston, MA
---------------------	---

Other Professional Positions:

1973-1975	Laboratory Technician, NIH #1-R01-8M-16933. University of Toledo, Toledo, OH.
1976-1979	Radiation Safety Officer, University of Toledo, Toledo, OH.
1979-1985	Unit Safety Officer, Committee on Research, Massachusetts General Hospital/Harvard Medical School, Boston, MA.

Awards and Honors:

1979-1981	Recipient of National Research Service Award, #1-F32-AM05798-01.
1983-1985	Co-principal investigator, " <i>Cysteamine: Its effects on prolactin secretion</i> ". NICHD; #HD17364. Effective dates: 7/1/83 - 6/30/86. Total direct costs = \$247,130.
1985-1986	Co-principal investigator, " <i>Peptides and brain function</i> ". NIADDK; #AM26252. Effective dates: 1/1/85 - 12/31/89. Total direct costs = \$909,307.
1987-1991	Principal investigator, " <i>Gonadal steroid modulation of brain-pituitary function</i> ". NICHD; #HD22199. Effective dates: 4/1/87 - 3/31/90. Total direct costs = \$209,710.
1987-1991	Co-investigator, " <i>Catecholamines and reproductive aging</i> ". NIA; #AG0201. Effective dates: 9/30/87 -08/31/91. Total direct costs = \$400,189.
1989-1991	Co-investigator, " <i>Nicotine in a long-term model for Alzheimer's disease</i> ". Council for Tobacco Research; #545. Effective dates: 1/1/91-12/31/91. Total direct costs = \$59,604.
1989-1991	Principal investigator, " <i>Growth factor modulation of in vitro anterior pituitary hormone secretion</i> ". Genentech, Inc. Effective dates: 7/1/89-6/30/91. Total direct costs = \$20,000.
1991-2005	Neurochemistry Core Director, " <i>Discovery of Novel Drugs for Alzheimer's Disease</i> ". NIA; Program project #AG10485. Effective dates: 10/1/91-9/30/04. Total direct costs = \$7,000,000.
1996	Phi Lambda Sigma - National Pharmacy Leadership Society.

Patents Awarded:

1987	Patent # 4,657,932. " <i>Method of treating prolactin-related disorders.</i> " Inventors: Joseph B. Martin, William J. Millard and Stephen M. Sagar. Award date: April 14, 1987.
2003	Patent # 6,500,643. " <i>Human High Affinity Choline Transporter.</i> " Inventors: Dong-Hai Wu, Yunrong Gu, William J. Millard and Yun-Ju He. Award date: December 31, 2002.

Major Committee

Assignments:

1976-1979	Radiation Safety Committee (Vice-Chairman), University of Toledo.
1986-2002	Health Center Animal Resource Advisory Committee, University of Florida.
1986-1989	External Pharm-D Curriculum Committee, College of Pharmacy, University of Florida.
1987-1988, 1989-1991	University Senate, University of Florida.
1988-1991	Division of Sponsored Research: Review Committee for Research Development Awards, University of Florida.
1988-1991	Biomedical Research Support Grant Committee, College of Pharmacy, University of Florida.
1988-1990	Graduate Studies Committee, College of Pharmacy, University of Florida.
1988-	Faculty Executive Committee, Center for the Neurobiology of Aging, University of Florida.
1990-1994, 1999-2001	Tenure and Promotion Committee, College of Pharmacy, University of Florida.
1990-1992	Academic Performance Committee, College of Pharmacy, University of Florida.
1991-1995	Curriculum Task Force, College of Pharmacy, University of Florida.
1992-1995	Financial Aid and Student Awards, College of Pharmacy, University of Florida.
1995-	Graduate Studies Committee, College of Pharmacy, University of Florida.
1995-	Executive Council, College of Pharmacy, University of Florida.
1995-1996	Leadership Council, College of Pharmacy, University of Florida.
1995-	Council of Graduate Deans, University of Florida
1995-	Health Center Research Deans Council, University of Florida
2001-2003	University Sick Leave Pool Committee
2001-	Institutional Animal Use and Care Committee.
2002-2003	AACP Research and Graduate Studies Committee Member
2003-	McKnight Brain Institute – Internal Advisory Board
2003-	HSC Parking and Traffic Committee
2004	University Land Use Facilities Planning Committee.

Professional Societies:

1983-	Society for Neuroscience.
1983-	Endocrine Society.
1986-	International Society of Neuroendocrinology.
1992-	American Pituitary Association.
1994-	American Association of Colleges of Pharmacy.
2000-	American Pharmacists Association

Teaching Experience:

1973-1974	Organized and taught laboratory courses in and Introductory Biology, Genetics, Physiology.
1975-1976	Developmental Biology, Nutrition and Immunology to both undergraduate and graduate students.
1976-1979	Invited lectures on endocrine physiology to undergraduate and graduate students. University of Toledo, Toledo, Ohio and Bowling Green State University, Bowling Green, Ohio.
1986-	Anatomy/Physiology, Pathophysiology and Pharmacology lectures to Pharmacy students. Advanced Mammalian Physiology, Neuropharmacology, Endocrinology, Advanced Topics and Research Methods in Pharmacodynamics to graduate students.

Teaching Honors/Awards:

- 1994-95 Teaching Improvement Program (TIP) Award - University of Florida, Gainesville, FL.
1997-98 Teacher of the Year – University of Florida, College of Pharmacy, Gainesville, FL

Major Research Interests:

1. Neural regulation of anterior pituitary hormone secretion.
2. Sexual dimorphisms in anterior pituitary hormone secretion.
3. Effects of aging on both neuroendocrine and endocrine regulation.
4. Neurotoxins and their effects on brain peptides and neurotransmitters.
5. Brain peptides and neurological disorders associated with metabolic disorders and aging.

BIBLIOGRAPHY

Original Papers:

1. Hatfield JS, Millard WJ, Smith CJV. Short-term influence of intraventricular administration of insulin on feeding in normal and diabetic rats. *Pharm Biochem Behav* 2:223-226 (1974).
2. Millard WJ. The ventromedial hypothalamic nucleus: Its role in the regulation of food consumption, body weight and growth hormone secretion in the male rat. *Ph.D. Dissertation*, University of Toledo, Toledo, Ohio (1979).
3. Millard WJ, Reppert SM, Sagar SM, Martin JB. Light-dark entrainment of the growth hormone ultradian rhythm in the rat is mediated by the arcuate nucleus. *Endocrinology* 108:2394-2396 (1981).
4. Millard WJ, Martin Jr JB, Audet J, Sagar SM, Martin JB. Evidence that reduced growth hormone secretion observed in monosodium glutamate-treated rats is due to a deficiency in growth hormone-releasing factor. *Endocrinology* 110:540-550 (1982).
5. Sagar SM, Landry D, Millard WJ, Badger TM, Arnold MA, Martin JB. Depletion of somatostatin-like immunoreactivity in the rat central nervous system. *J Neurosci* 2:225-231 (1982).
6. Badger TM, Sagar SM, Millard WJ, Martin JB, Rosenblum PM, Levenson SE. Effects of cysteamine on the hypothalamic-pituitary-gonadal axis of adult male rats. *Life Sci* 30:245-252 (1982).
7. Millard WJ, Sagar SM, Landis DMD, Martin JB, Badger TM. Cysteamine: A potent and selective depletor of pituitary prolactin. *Science* 217:452-454 (1982).
8. Badger TM, Millard WJ, Martin JB, Rosenblum PM, Levenson SE. Hypothalamic-pituitary-gonadal function of adult rats treated neonatally with monosodium glutamate. *Endocrinology* 111:2031-2038 (1982).
9. Millard WJ, Sagar SM, Badger TM, Martin JB. Cysteamine effects in growth hormone secretion in the male rat. *Endocrinology* 112:509-517 (1983).
10. Millard WJ, Sagar SM, Badger TM, Carr DB, Arnold MA, Spindel E, Kasting NW, Martin JB. The effects of cysteamine on thyrotropin and β -endorphin secretion in the rat. *Endocrinology* 112:518-525 (1983).
11. Simpkins JW, Estes KS, Millard WJ, Sagar SM, Martin JB. Cysteamine depletes prolactin in young and old hyperprolactinemic rats. *Endocrinology* 112:1889-1891 (1983).
12. Millard WJ, Sagar SM, Simpkins JW, Owens RE, Friesen HG, Martin JB. Cysteamine induces depletion of both immunological and biological prolactin activity in the anterior pituitary and blood of the rat. *Endocrinology* 113:2161-2167 (1983).
13. Riskind PN, Millard WJ, Martin JB. Opiate modulation of the anterior pituitary hormonal response during suckling in the rat. *Endocrinology* 114:1232-1237 (1984).
14. Riskind PN, Millard WJ, Martin JB. Evidence that thyrotropin-releasing hormone is not a major prolactin-releasing factor during suckling in the rat. *Endocrinology* 115:312-315 (1984).
15. Gabriel SM, Simpkins JW, Millard WJ. The effects of chronic naloxone on pituitary hormone secretion in female rats. *Brain Res Bull* 12:359-363(1984).
16. Kumar MSA, Besch EL, Millard WJ, Sharp DC, Leadem CA. Effect of short photoperiod on hypothalamic methionine-enkephalin and LHRH content and serum β -endorphin-like immunoreactivity (β -END-LI) levels in golden hamsters. *J Pineal Res* 1:197-205 (1984).

17. Badger TM, Millard WJ, McCormick GF, Bowers CY, Martin JB. The effects of growth hormone (GH)-releasing peptides on GH secretion in perfused pituitary cells of adult male rats. *Endocrinology* 115:1432-1438 (1984).
18. Weinstein LA, Landis DMD, Sagar SM, Millard WJ, Martin JB. Cysteamine depletes prolactin, but does not alter the structure of prolactin containing granules in the anterior pituitary. *Endocrinology* 115:1543-1550 (1984).
19. Simpkins JW, Taylor ST, Gabriel SM, Katovich MJ, Millard WJ. Evidence that chronic hyperprolactinemia effects skin temperature regulation through an opioid mechanism. *Neuroendocrinology* 39:321-329 (1984).
20. Kumar MSA, Patel V, Millard WJ. Effect of chronic administration of delta⁹-tetrahydrocannabinol on endogenous opioid peptides and catecholamine levels in the diencephalon and plasma of the rat. *Substance and Alcohol Actions/Misuse* 5:201-210 (1985).
21. McCormick GM, Millard WJ, Badger TM, Bowers CY, Martin JB. Dose-response characteristics of various peptides with growth hormone-releasing activity in the unanesthetized male rat. *Endocrinology* 117:97-105 (1985).
22. Sagar SM, Millard WJ, Martin JB, Murchison SC. The mechanism of action of cysteamine in depleting prolactin immunoreactivity. *Endocrinology* 117:591-600 (1985).
23. Gabriel SM, Simpkins JW, Millard WJ. Changes in anterior pituitary hormone secretion and hypothalamic catecholamine metabolism during morphine withdrawal in the female rat. *Brain Res* 346:15-21 (1985).
24. Patel V, Borysenko PV, Kumar MSA, Millard WJ. Effects of acute and subchronic delta⁹-tetrahydrocannabinol administration on the plasma catecholamine, β -endorphin and corticosterone levels and splenic natural killer cell activity in rats. *Proc Soc Exp Biol Med* 180:400-404 (1985).
25. O'Sullivan DM, Millard WJ, Martin JB, Martin RJ. Growth hormone secretion in genetic large (LL) and small (SS) rats. *Endocrinology* 119:1948-1953 (1986).
26. Millard WJ, Politch JA, Martin JB, Fox TO. Growth hormone secretory patterns in androgen-resistant (testicular feminized, tfm) rats. *Endocrinology* 119:2655-2660 (1986).
27. Kumar AM, Solomon J, Patel V, Kream RM, Drieze J., Millard WJ. Early exposure to delta⁹-tetrahydrocannabinol (THC) influences neuroendocrine and reproductive functions in female rats. *Neuroendocrinology* 44:260-264 (1986).
28. Truong T, Sagar SM, Millard WJ, Shaw JL. Cysteamine induces cataracts in newborn rats. *Invest Ophthalmol Vis Sci* 28:1710-1713 (1987).
29. Millard WJ, O'Sullivan D, Riskind PN. Effect of cysteamine on suckling-induced prolactin secretion in the rat. *Life Sci* 41:2255-2260 (1987).
30. Arendash GW, Millard WJ, Dunn AJ, Meyer EM. Long-term neuropathological and neurochemical effects of nucleus basalis lesions in the rat. *Science* 238:952-956 (1987).
31. Mouton PR, Meyer EM, Dunn AJ, Millard W, Arendash GW. Induction of cortical cholinergic hypofunction and memory retention deficits through intracortical AF64A infusions. *Brain Res* 444:104-118 (1988).
32. Bridges RS, Millard WJ. Growth hormone is secreted by ectopic pituitary grafts and stimulates maternal behavior in rats. *Horm Behav* 122:194-206 (1988).
33. Poulakos JJ, Shakar R, Millard WJ, Meyer EM. The primary neuron enriched culture from rat brain as a model for studying cholinergic neuropeptide-Y interactions. *Advances in Gene Technology: Molecular Neurobiology and Neuropharmacology* pg 118 (1989).
34. Gabriel SM, Millard WJ, Koenig JI, Badger TM, Russell WR, Maiter DM, Martin JB. Sexual and developmental differences in peptides regulating growth hormone secretion in the rat. *Neuroendocrinology* 50:299-307 (1989).
35. Arendash GW, Millard WJ, Dawson Jr. R, Dunn AJ, Meyer EM. Different long-term effects of bilateral and unilateral nucleus basalis lesions on rat cerebral cortical neurotransmitter content. *Neurochem Res* 14:1113-1118 (1990).
36. Donaghue KC, Badger TM, Millard WJ, Frisch LS, Russell WE. Absence of ultradian rhythm or diurnal variation of circulating immunoreactive somatomedin-C in rats. *Neuroendocrinology* 52:1-8 (1990).
37. Millard WJ, Romano TM, Simpkins JW. Growth hormone and thyrotropin secretory profiles and provocative testing in aged rats. *Neurobiol Aging* 11:229-235 (1990).
38. Millard WJ, Arendash GW, Dunn AJ, Meyer EM. Effects of nucleus basalis lesions on cerebral cortical concentrations of corticotropin-releasing hormone (CRH)-like immunoreactivity in the rat. *Neurosci Lett* 113:233-239 (1990).
39. Simpkins JW, Millard WJ, Katovich MJ, Knight S. Glucose modulation of skin temperature responses during morphine withdrawal in the rat. *Psychopharmacology* 102:213-220 (1990).

40. Berglund LA, Millard WJ, Gabriel SM, Simpkins JW. Opiate-thyroid hormone interactions in the regulation of TSH secretion in the rat. *Neuroendocrinology* 52:303-308 (1990).
41. Millard WJ, Romano TM, Bodor N, Simpkins JW. GH secretory dynamics in animals administered estradiol utilizing a chemical delivery system. *Pharmaceut Res.* 7:1011-1018 (1990).
42. Simpkins JW, Andreadis DK, Millard WJ, Katovich MJ. The effect of cellular glucoprivation on skin temperature regulation in the rat. *Life Sci* 47:107-115 (1990).
43. Poulakos JJ, Meyer EM, Pruyssers CR, Millard WJ. Neuropeptide Y-Cholinergic interactions in neocortical tissue. *Ann NY Acad Sci* 611:219-225 (1990).
44. Masters BA, Pruyssers CR, Millard WJ, Meyer EM, Poulakos JJ. Pre-proneuro-peptide Y mRNA expression in glial cell cultures of the neonate but not 21 day old rat brain. *Ann NY Acad Sci* 611:522-524 (1990).
45. Badger TM, Millard WJ, Owens SM, LaRovere J, O'Sullivan D. Effects of gonadal steroids on clearance of growth hormone at steady state in the rat. *Endocrinology* 128:1065-1072 (1991).
46. Wood TL, Berelowitz M, Gelato M, Roberts Jr C, LeRoith D, Rechler MM, Millard WJ, McKelvy JF. Hormonal regulation of rat hypothalamic neuropeptide mRNAs: effect of hypophysectomy and hormone replacement on GRF, SRIF and the insulin-like growth factors. *Neuroendocrinology* 53:298-305 (1991).
47. Millard WJ, Romano TM, Layden MP, Russell WE, Martin RJ. Growth hormone secretion in the obese male rat: modulation by the gonadal and thyroid axes. *Growth, Development and Aging* 55:91-103 (1991).
48. Simpkins JW, Swager D, Millard WJ. Evaluation of the sites of opioid influence on anterior pituitary hormone secretion using a quaternary opiate antagonist. *Neuroendocrinology* 54:384-390 (1991).
49. Cugini Jr CD, Millard WJ, Leidy Jr JW. Signal transduction systems in growth hormone-releasing hormone and somatostatin release from perfused rat hypothalamic fragments. *Endocrinology* 129:1355-1362 (1991).
50. Millard WJ, Romano TM. Comparison of efficacy of cysteamine in depleting prolactin immunoreactivity in different hyperprolactinemic animal models. *Life Sci* 49:1635-1642 (1991).
51. Singh M, Simpkins JW, Layden MP, Romano TM, Millard WJ. Opiate modulation of growth hormone secretion is compromised during the steroid-induced LH surge. *Neuroendocrinology* 55:214-220 (1992).
52. Peris J, Coleman-Hardee M, Millard WJ. Cocaine *in utero* enhances the behavioral response to cocaine in adult rats. *Pharmacol Biochem Behav* 42:509-515 (1992).
53. Singh M, Millard WJ, Layden MP, Romano TM, Simpkins JW. Opiate stimulation of prolactin secretion is reversed by ovarian hormone treatment. *Neuroendocrinology* 56:195-203 (1992).
54. Gabriel SM, Hunnicut EH, Millard WJ, Badger TM, Nathanson JA. Influence of *in vivo* reproductive endocrine state on growth hormone-releasing factor stimulated adenylate cyclase activity in anterior pituitary fragments. *Neuroendocrinology* 57:63-69 (1993).
55. Simpkins JW, Millard WJ, Berglund LE. Effects of chronic stimulation or antagonism of opiate receptors on GH secretion in male and female rats. *Life Sci.* 52:1443-1450 (1993).
56. Leidy Jr JW, Romano TM, Millard WJ. Developmental and sex-related changes of the growth hormone axis in lean and obese Zucker rats. *Neuroendocrinology* 57:213-223 (1993).
57. Poulakos JJ, Millard WJ, Meyer EM. Modulation of neuropeptide Y expression in rat brain neuronal cultures. *Dev Brain Res* 74:25-29 (1993).
58. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-1 and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue octreotide: a potential treatment for ocular neovascularization. *Reg Pept* 48:267-278 (1993).
59. Yeh JK, Aloia JF, Tierney JM, Chen M, Ling N, Koo H, Millard WJ. Effect of growth hormone administration and treadmill exercise on serum and skeletal IGF-1 in rats. *Am J Physiol* 266:E129-E135 (1994).
60. de Fiebre CM, Wu P, Notabartolo D, Millard WJ, Meyer EM. Differential adenoassociated virus vector-driven expression of a neuropeptide Y gene in primary rat brain astroglial cultures after transfection with Sendai virosomes versus Lipofectin™. *Neurochem Res* 19:643-648 (1994).
61. Wu P, Ziska D, Bonell MA, Grouzmann E, Millard WJ, Meyer EM. Neuropeptide Y gene expression driven by an adeno-associated virus vector in human post-mitotic and dividing neuroblastoma cells. *Molec Brain Res* 24:27-33 (1994).
62. Singh M, Meyer EM, Millard WJ, Simpkins JW. Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. *Brain Res* 644:305-212 (1994).
63. Leung K-C, Millard WJ, Peters E, Markus I, Baumbach WR, Barnard R, Ho KKY. Measurement of growth hormone (GH) binding protein in the rat by a ligand immunofunctional assay. *Endocrinology* 136:379-385 (1995).

64. Wu P, de Fiebre CM, Millard WJ, Elmstrom K, Gao Y, Meyer EM. Sendai virosomal infusion of an adeno-associated virus-derived construct containing neuropeptide Y into primary rat brain cultures. *Neurosci Lett* 190:73-76 (1995).
65. Wu P, de Fiebre CM, Millard WJ, King MA, Wang S, Bryant SO, Gao Y-P, Elmstrom K, Martin EJ, Grouzmann E, Meyer EM. Characterization of a neuropeptide Y gene delivery system for neurons and rat brain. *Gene Therapy* 3:246-253 (1996).
66. Masten SA, Millard WJ, Karlix J, Shiverick KT. Evaluation of immune parameters and lymphocyte prolactin production after chronic administration of cocaine to pregnant rats. *J Pharmacol Exper Therapeut.* 277:1090-1096 (1996).
67. Leidy Jr, JW, Daniels KL, Millard WJ. Solid phase radioimmunoassay and chemiluminoimmunoassay for somatostatin in unextracted rat plasma. *J Neurosci Meth* 68:7-13 (1996).
68. Müller S, Ho B, Gambus P, Millard W, Hochhaus G. An HPLC/RIA method for Dynorphin A1-13 and its main metabolites in human blood. *J Pharm Biomed Anal* 16:101-109 (1997).
69. Dawson Jr R, Pelleymounter MA, Millard WJ, Liu S, Eppler B. Attenuation of leptin-mediated effects by monosodium glutamate (MSG)-induced arcuate nucleus damage. *Am J Physiol*, 273:E202-E207 (1997).
70. Wang S, Millard WJ, and Meyer EM. NGF gene expression in dividing and non-dividing cells from AAV derived constructs. *Neurochem Res*, 23:779-788 (1998).
71. Dawson Jr R, Marschall EG, Chan KC, Millard WJ, Eppler B, Patterson TA. Neurochemical and neurobehavioral effects of neonatal administration of β -N-methylamino-L-alanine and 3,3'-iminodipropionitrile. *Neurotox & Teratol.* 20:181-192 (1998).
72. Eppler B, Patterson TA, Zhou W, Millard WJ, Dawson Jr R. Kainic acid (KA)-induced seizures in Sprague-Dawley rats and the effect of dietary taurine (TAU) supplementation or deficiency. *Amino Acids* 16:133-147 (1999).
73. Severgnini S, Lowenthal DT, Millard WJ, Simmen FA, Borst SE. Altered IGF-1 and IGFbps in senescent male and female rats. *J Gerontol*, 54A(3): B111-B115 (1999).
74. Li Y, Papke RL, Martin EJ, He Y-J, Millard WJ, Meyer EM. Characterization of the neuroprotective and toxic effects of alpha7 nicotinic receptor activation in PC12 cells. *Brain Res.* 830:218-225 (1999).
75. Martin RL, Perez E, He Y-J, Dawson Jr R, Millard WJ. Leptin resistance is associated with hypothalamic leptin receptor mRNA protein downregulation. *Metabolism* 49:1479-1484 (2000).
76. Yang S-H, He Z, Wu SS, He Y-J, Cutright J, Millard WJ, Day AL, Simpkins JW. 17- β Estradiol can reduce secondary ischemic damage and mortality of subarachnoid hemorrhage. *J. Cerebral Blood Flow and Metabolism*, 21:174-181 (2001).
77. Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R. Myotoxicity studies of injectable biodegradable *in-situ* forming drug delivery systems. *Internat J Pharmaceutics*, 212:11-18 (2001).
78. Li Y, Meyer EM, Walker DW, Millard WJ, He Y-J, King MA. Alpha7 nicotinic receptor activation inhibits ethanol-induced mitochondrial dysfunction, cytochrome C release and neurotoxicity in primary rat hippocampal neuronal cultures. *J Neurochem.* 81:853-858 (2002).
79. Klein RL, Hamby ME, Sonntag CF, Millard WJ, King MA, Meyer EM. Measurements of vector-derived neurotrophic factor and green fluorescent protein levels in the brain. *Methods* 28:286-292 (2002).
80. Joseph CG, Bauzo RM, Xiang Z, Shaw AM, Millard WJ, Haskell-Luevano C. Elongation studies of the human agouti-related protein (ARGP) core decapeptide (Ye[CRFFNAC]Y), results in antagonism at the mouse melanocortin-3 receptor. *Peptides* 24:263-270 (2003).
81. Wu K, Klein RL, Meyers CA, King MA, Hughes JA, Millard WJ, Meyer EM. Long-term neuronal effects and disposition of ectopic preproNGF gene transfer into rat septum. *Human Gene Therapy* 14:1463-1472 (2003).
82. Wilczynski A, Wang XS, Joseph CG, Xiang Z, Bauzo RM, Scott JW, Shaw AM, Millard WJ, Richards NG, Haskell-Luevano C. Identification of putative agouti-related protein (87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands. *J Med Chem.* 47:2194-2007 (2004).
83. Wilczynski A, Wang XS, Bauzo RM, Xiang Z, Shaw AM, Millard WJ, Richards NG, Edison AS, Haskell-Luevano C. Structural characterization and pharmacology of a potent (Cys101-Cys119, Cys110-Cys117) bicyclic agouti-related protein (AGRP) melanocortin receptor antagonist. *J Med Chem.* 47:5662-5673 (2004)
84. Shaw AM, Irani BG, Moore MC, Haskell-Luevano C, Millard WJ. Ghrelin-induced food intake and growth hormone secretion are altered in melanocortin 3 and 4 receptor knockout mice. *Peptides* 26:1720-1727 (2005).
85. Proneth B, Xiang Z, Pogozheva ID, Litherland SA, Gorbatyuk OS, Shaw AM, Millard, WJ, Mosberg HI, Haskell-Luevano C. Molecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism. *Chem. Biol. Drug. Des.*, 67:215-229 (2006).

86. Xiang Z, Litherland SA, Sorensen NB, Proneth B, Palusak R, Wood MS, Shaw AM, Millard WJ, Haskell-Luevano C. Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist. *Biochemistry* 45:7277-7288 (2006).
87. Levin GM, Bowles TM, Ehret MJ, Langae T, Yan JY, Johnson JA, Millard WJ. Assessment of Human Serotonin 1A Receptor Polymorphisms and SSRI Responsiveness. *Mol Diag Ther.* 11:155-160 (2007).
88. Zhimin X, Pogozheva ID, Sorenson NB, Wilczynski AM, Holder JR, Litherland SA, Millard WJ, Mosberg HI, Haskell-Luevano C. Peptide and Small Molecules Rescue Functional Activity and Agonist Potency of Dysfunctional Human Melanocortin-4 Receptor Polymorphisms. *Biochemistry.* 46:8273-8287 (2007).

Reviews and Book Chapters:

1. Millard WJ, Martin JB. Opioid modulation of human growth hormone secretion. In: *Opioid Modulation of Endocrine Function*. Delitala G, Motta M, Serio M (eds), Raven Press, NY. pp 111-123 (1984).
2. Martin JB, Millard WJ, McCormick G, Kasting N, Fukata J. Somatostatin: mechanisms of release. In: *Endocrinology: Proceedings 7th International Congress of Endocrinology*. Labrie F, Proulx L (eds), Elsevier Science Publishing, Amsterdam. pp 835-841 (1984).
3. Simpkins JW, Millard WJ, Gabriel SM, Soltis EE. Noradrenergic methods in neuroendocrinology. In: *Handbook of Pharmacologic Methodologies for the Study of the Neuroendocrine System*. Steger RS, Johns A (eds), CRC Press Inc, Boca Raton, FL. pp 1-63 (1985).
4. Millard WJ, Sagar SM, Martin JB. Cysteamine-induced depletion of somatostatin and prolactin. *Fed Proc.* 44:2546-2550 (1985).
5. Martin JB, Millard WJ. Brain regulation of growth hormone secretion. *J Anim Sci.* 63(Suppl. 2):11-26 (1986).
6. Millard WJ, O'Sullivan DM, Fox TO, Martin JB. Sexually dimorphic patterns of growth hormone secretion. In: *The Episodic Secretion of Hormones*. Crowley Jr WF, Hofler J (eds), John Wiley and Sons, NY. pp 287-304 (1987).
7. Millard W, Fox TO, Badger TM, Martin JB. Gonadal steroid modulation of growth hormone secretory patterns in the rat. In: *Acromegaly*. Robbins RJ, Melmed S (eds), Plenum Press, NY. pp 139-150 (1987).
8. Simpkins JW, Millard WJ. Influence of age on neurotransmitter function. In: *Endocrinology and Metabolism Clinics of North America - Endocrinology and Aging*. Sacktor B (ed), W.B. Saunders, Philadelphia, PA, vol 16:893-917 (1987).
9. Millard WJ. Central regulation of growth hormone secretion. In: *Animal Growth Regulation*. Campion DR, Martin RJ, Hausman GJ (eds), Plenum Press, NY, pp 237-255 (1989).
10. Arendash GW, Millard WJ, Shaw J, Meyer EM. Transneuronal neurochemical and neuropathological changes induced by nucleus basalis lesions: a possible degenerative mechanism in Alzheimer's Disease. In: *Novel Approaches to the Treatment of Alzheimer's Disease*. Meyer EM, Simpkins JW, Yamamoto J (eds), Plenum Press, New York, pp 235-254 (1989).
11. Poulakos JJ, Arendash GW, Millard WJ, Shak-Shie N, Meyer EM. Cholinergic-neuropeptide Y interactions in the rat cerebral cortex: towards a model for the transsynaptic effects of cholinergic transmission. In: *Novel Approaches to the Treatment of Alzheimer's Disease*. Meyer EM, Simpkins JW, Yamamoto J (eds), Plenum Press, New York, pp 269-277 (1989).
12. Meyer E, Millard W, Poulakos J, Arendash GW. Neurochemical and behavioral effects of bilateral nucleus basalis lesions in the aged rat. In: *Biomedical Advances in Aging*. Goldstein AL (ed), Plenum Press, New York, pp 491-496 (1990).
13. Millard WJ. Potential therapeutic use of growth hormone in the metabolic treatment of Alzheimer's Disease. In: *Treatment of Dementias: A New Generation of Progress*. Meyer EM, Simpkins JW, Yamamoto JY, Crews F (eds), Plenum Press, New York, pp 427-450 (1992).
14. Borst SE, Millard WJ, Lowenthal DT. Growth hormone, exercise and aging: the future of growth axis therapy for the elderly. *J Am Geriatr Soc* 42:528-535 (1994).
15. Meyer EM, Wu P, King M, de Fiebre CM, Millard WJ, Bryant S, Gao Y-P. A novel gene delivery system for neuroactive peptides in brain tissue. In: *Alzheimer's and Parkinson's Diseases: Recent Advances, Behavioral Biology series - vol 44*. Hanin I, Fisher A, Yoshida M (eds), Plenum Press, New York, pp 699-708 (1995).
16. Meyer EM, Wu P, King MA, Millard WJ. AAV-derived vectors for neuronal gene delivery: *in vitro* to *in vivo* considerations. In: *Treatment of Alzheimer's and Parkinson's Diseases* Hanin I, Fisher A, Yoshida M (eds), Raven Press, pg 497-501 (1996).

- Medrano TA, Conliffe PR, Novak DA, Millard WJ, Shiverick KT. Differential effects of protein malnutrition in pregnant rats on the expression of placental prolactin-like proteins. In: *Trophoblast Research*: Takayma M, Hata T, Taki I, Miller RK (eds), University of Rochester Press, Rochester, New York, pp 427-442 (1999).

Monographs, Bulletins and Proceedings:

- Lowrey TW, DeCapito CA, Millard WJ. Cholesterol management in Graves Disease. Bulletin #20, National Graves' Disease Foundation, Jacksonville, FL 32211 (1992).
- DeCapito CA, Lowrey TW, Millard WJ. Beta blockers in Graves Disease. Bulletin #21, National Graves Disease' Foundation, Jacksonville, FL 32211 (1992).
- Lowrey TW, DeCapito CA, Millard WJ. Tapazole and propylthiouracil in Graves Disease. Bulletin #22, National Graves' Disease Foundation, Jacksonville, FL 32211 (1992).
- DeCapito CA, Lowrey TW, Millard WJ. Thyroid hormone preparations and commonly used drugs in Graves' Disease. Bulletin #23, National Graves Disease Foundation, Jacksonville, FL 32211 (1993).
- Lin AY, Altere RJ, Harris WT, Sims PJ, Ganther JM, Meyer SM, Kradjan WA, Bennett M, Crabtree BL, Goode JV, Love RC, Rospond RM, Sorenson TD, Flynn AA, Callery PS, Barner JC, Beck WT, Bridges RJ, Chrisholm MA, Levin RM, Millard WJ, Miller KW. Leadership: The nexus between challenge and opportunity: Reports of the 2002-03 academic affairs, professional affairs, and research and graduate affairs committees. *Am J Pharm Ed* 67(Suppl):1-17 (2003).
- Haskell-Luevano CH, Xiang Z, Wilczynski A, Haskell KR, Anderson AM, Litherland SA, Millard WJ, Pogozheva ID, Mosberg HI, Sorenson NB. Discovery of a ligand that compensates for decreased endogenous agonist potency of melanocortin-4 receptor polymorphisms identified in obese humans. In: *Peptides for Youth*: Escher E, Lubell WD, Del Volle S (eds), American Peptide Society (2007)

Abstracts:

- Millard WJ, Gordon K, Martin Jr JB, Audet J, Sagar SM, Martin JB. Effects of morphine (MS), α -melanocyte-stimulating hormone (α -MSH) and pentobarbital (PB) on plasma growth hormone (GH) and prolactin (PRL) in monosodium glutamate (MSG)-treated rats. *Fed Proc* 39:980 (1980).
- Millard WJ, Reppert SM, Sagar SM, Martin JB. Dissociation of the neural components governing the light-dark (L/D) entrainment of pineal activity and drinking behavior from that of episodic growth hormone (GH) secretion in the rat. *Physiologist* 23:144 (1980).
- Badger TM, Millard WJ, Martin JB, Rosenblum PM, Clement RE. Hypothalamic-pituitary function in MSG-treated rats: LH and LHRH release. *Fed Proc* 40:433 (1981).
- Sagar SM, Landry D, Badger TM, Millard WJ, Arnold MA, Martin JB. Depletion of somatostatin-like immunoreactivity from rat central nervous system by cysteamine. *Neurology* 31:63 (1981).
- Badger TM, Sagar SM, Millard WJ, Martin JB, Rosenblum PM, Levenson S. Cysteamine inhibits hypothalamic-pituitary-gonadal axis in adult male rats. *Prog 63rd Annual Meeting, Endocrine Society*. pg 286 (1981).
- Badger TM, Millard WJ, Martin JB, Rosenblum PM, Levenson SE. The effects of castration on the hypothalamic-pituitary axis of monosodium glutamate treated rats. *Physiologist* 24:49 (1981).
- Millard WJ, Sagar SM, Badger TM, Martin JB. Cysteamine: Its effects on pulsatile growth hormone (GH) and TSH secretion in the rat. *Fed Proc* 41:1489 (1982).
- Sagar SM, Millard WJ, Landis DMD, Martin JB. Depletion of pituitary prolactin by cysteamine. *Clin Res* 40:493A (1982).
- Millard WJ, Politch JA, Martin JB, Fox TO. Analysis of sexually dimorphic patterns of growth hormone secretion in rats: effects of gonadal steroids during the neonatal period. *Prog 64th Annual Meeting, Endocrine Society*. pg 325 (1982).
- Millard WJ, Politch JA, Martin JB, Fox TO. Analysis of the patterns of growth hormone secretion in testicular-feminized (tfm) rats. *Prog 12th Annual Meeting, Society for Neuroscience*. pg 197 (1982).
- Millard WJ, Sagar SM, Owens RE, Badger TM, Martin JB. Cysteamine-induced depletion of both immunological and biological prolactin activity in the anterior pituitary and blood of the rat. *Prog 65th Annual Meeting, Endocrine Society*. pg 162 (1982).
- Riskind PN, Millard WJ, Martin JB. Opiate-modulation of anterior pituitary hormone release during suckling. *Prog 65th Annual Meeting, Endocrine Society*. pg 236 (1983).

13. Gabriel SM, Simpkins JW, Millard WJ. Changes in anterior pituitary hormone secretion and hypothalamic catecholamine metabolism during morphine withdrawal in the rat. *Prog 13th Annual Meeting, Society for Neuroscience*. pg 703 (1983).
14. Badger TM, Millard WJ, McCormick GF, Martin JB, Bowers CY. The effects of two growth hormone (GH) releasing peptides on GH secretion in perfused pituitary cells of adult male rats. *Prog 7th International Congress of Endocrinology*. pg 327 (1984).
15. Gabriel SM, Simpkins JW, Millard WJ. Long-term ovariectomy does not modify the age-associated reduction in hypothalamo-hypophyseal β -endorphin concentrations in the female rat. *Prog 7th International Congress of Endocrinology*. pg 684 (1984).
16. Marshall PE, Martin JB, Millard WJ, Sagar SM, Landis DMD. The distribution of growth hormone releasing factor (GRF) in the human hypothalamus. *Prog 7th International Congress of Endocrinology*. pg 1017 (1984).
17. Millard WJ, McCormick GF, Badger TM, Bowers CY, Martin JB. Dose-response characteristics of various peptides with growth hormone (GH)-releasing activity in the unanesthetized male rat. *Prog 7th International Congress of Endocrinology*. pg 1148 (1984).
18. Riskind PN, Millard WJ, Soukup J, Martin JB. Neuroendocrine responses in undisturbed lactating rats during multiple successive suckling episodes. *Prog 7th International Congress of Endocrinology*. pg 1191 (1984).
19. McCormick GF, Millard WJ, Badger TM, Martin JB. Gonadal steroid modulation of growth hormone-releasing factor-stimulated growth hormone secretion. *Prog 14th Annual Meeting, Society for Neuroscience*. pg 1214 (1984).
20. Kumar MSA, Patel V, Kream R, Dreez J, Millard WJ. Effect of early exposure to delta⁹-tetrahydrocannabinol (THC) on post-pubertal reproductive functions. *Fed Proc* 44:1472 (1985).
21. Millard WJ, Badger TM, Fox TO, Martin JB. Gonadal steroid modulation of growth hormone (GH) secretory patterns in adult male and female rats. *Prog 67th Annual Meeting, Endocrine Society*. pg 194 (1985).
22. Riskind PN, Millard WJ. Absence of early-morning prolactin secretion on days 5-7, but not days 15-17 of lactation in the rat. *Prog 67th Annual Meeting, Endocrine Society*. pg 44 (1985).
23. Sagar SM, Millard WJ, Martin JB, Murchison SC. The mechanism of action of cysteamine in depleting prolactin immunoreactivity. *Prog 5th International Washington Spring Symposium, Washington D.C.* pg 71 (1985).
24. Millard WJ, Badger TM, Fox TO, Martin JB. Effects of short-term exposure to gonadal steroids on growth hormone (GH) secretory patterns in adult male and female rats. *Prog 15th Annual Meeting, Society for Neuroscience*. pg 1299 (1985).
25. Riskind PN, Millard WJ, Martin JB. Effect of cysteamine (CSH) on suckling-induced prolactin (PRL) secretion in the rat. *Prog 15th Annual Meeting, Society for Neuroscience*. pg 1298 (1985).
26. Clark JT, Kalra PS, Millard WJ, Katovich MJ. Effects of MtTW15 secreting tumors on copulatory behavior, penile reflexes, plasma hormones and organ weights. *Fed Proc* 45:889 (1986).
27. Badger TM, O'Sullivan D, LaRovere J, Millard WJ, Martin JB. The effects of testosterone on metabolic clearance rate of GH in female rats. *Prog First International Congress of Neuroendocrinology*. pg 67 (1986).
28. Berglund LA, Millard WJ, Gabriel SM, Simpkins JW. Opiate-thyroid hormone interactions in the regulation of TSH secretion in the rat. *Prog First International Congress of Neuroendocrinology*. pg 38 (1986).
29. Berglund LA, Millard WJ, Simpkins JW. Reduced morphine responsiveness on proestrous afternoon in the rat. *Prog 16th Annual Meeting, Society for Neuroscience*. pg 1384 (1986).
30. Gabriel SM, Millard WJ, Badger TM, Martin JB. Measurement of hypothalamic growth hormone-releasing factor (rGRF) in male and female rats. *Prog 16th Annual Meeting, Society for Neuroscience*. pg 1522 (1986).
31. Arendash GW, Meyer EM, Millard WJ, Dunn AJ. Nucleus basalis magnocellularis (nBM) lesions increase cortical somatostatin levels while inducing cortical cholinergic hypofunction. *Prog 16th Annual Meeting, Society for Neuroscience*. pg 1245 (1986).
32. Cameron DF, Katovich MJ, Papadi G, Friedman J, Kalra P, Millard WJ. Male reproductive dysfunction in the hyperprolactinemic rat. *Physiologist* 29:131 (1986).
33. Badger TM, Crowley WF, Millard WJ, Mak P, Babu GN. Growth hormone secretion following gonadotropin releasing hormone or bombesin administration in perfused rat pituitary cells. *Prog 69th Annual Meeting, Endocrine Society*. pg 48 (1987).
34. Bridges RS, Dunckel PT, Millard WJ. Growth hormone involvement in the stimulation of maternal behavior in rats. *Prog 69th Annual Meeting, Endocrine Society*. pg 202 (1987).
35. Berglund LA, Millard WJ, Simpkins WJ. Chronic opiate stimulation alters GH secretory patterns in adult rats. *International Symposium on Growth Hormone - Serono, Tampa*. pg 36 (1987).
36. Clark JT, Millard WJ, Katovich MJ. Large increases in circulating growth hormone (GH) and prolactin (PRL) levels are associated with deficits in sexual behavior in male rats. *International Symposium on Growth Hormone - Serono, Tampa*. pg 39 (1987).

37. Arendash GW, Meyer EM, Dunn AJ, Dawson R, Millard WJ. Nucleus basalis magnocellularis (nBM) lesions induce abnormal cortical levels of somatostatin, neuropeptide Y (NPY), corticotropin-releasing hormone (CRH), and glutamine. *Prog 17th Annual Meeting, Society for Neuroscience*. pg 1074 (1987).
38. Simpkins JW, Millard WJ, Katovich MJ. Glucose modifies the opiate withdrawal response. *FASEB Journal* 2:1197 (1988).
39. Millard WJ, Romano TM, Martin RJ. Growth hormone (GH) and thyrotropin (TSH) secretory patterns in the adult Zucker obese rat. *Prog 70th Annual Meeting, Endocrine Society*. pg 120 (1988).
40. Poulakos JJ, Millard WJ, Raizada MK, Meyer EM. The primary neuron-enriched culture from rat brain as a model for studying somatostatin (SS) and neuropeptide Y (NPY) turnover. *Prog 18th Annual Meeting, Society for Neuroscience*. pg 876 (1988).
41. Jantzen PT, Meyer EM, Millard WJ, Dunn AJ, Arendash GW. Neonate nucleus basalis lesions result in cortical cholinergic hypofunction and cognitive deficits during adulthood. *Prog 18th Annual Meeting, Society for Neuroscience*. pg 1274 (1988).
42. Millard WJ, Romano TM, Simpkins JW. Growth hormone (GH) and thyrotropin (TSH) secretory profiles and provocative testing in aged male and female rats. *Seventh Annual Symposium on Geriatrics and Gerontology; Endocrine Function and Aging*. pg 49 (1988).
43. Arendash G, Mazziota J, Dillela V, Mouton P, Randhawa R, Sengstock G, Millard W, Shaw J, Meyer E. The nucleus basalis-lesioned rat: transsynaptic neurochemical and neuropathological effects. *First Suncoast Workshop on the Neurobiology of Aging*. pg 19 (1989).
44. Poulakos JJ, Shakar R, Millard WJ, Meyer EM. The primary neuron-enriched culture from rat brain as a model for studying cholinergic neuropeptide Y interactions. *First Suncoast Workshop on the Neurobiology of Aging*. pg 71 (1989).
45. Simpkins JW, Katovich MJ, Millard WJ, Knight S. Effects of acute hyper- and hypoglycemia on the skin temperature response to morphine withdrawal in the rat. *FASEB Journal* 3:A701 (1989).
46. Simpkins JW, Berglund LA, Siciliano W, Millard WJ. Blockade of morphine stimulated growth hormone release during the steroid-induced LH surge. *Prog 71st Annual Meeting, Endocrine Society*. pg 77 (1989).
47. Millard WJ, Romano TM, Simpkins JW. GH secretory dynamics in animals administered gonadal steroids utilizing a chemical delivery system. *2nd International Pituitary Congress*. pg M-15 (1989).
48. Sjak-Shie NN, Burks J, Millard WJ, Meyer EM. Long term nicotine treatment in rats with bilateral nucleus basalis lesions. *Prog 19th Annual Meeting, Society for Neuroscience*. pg 679 (1989).
49. Poulakos JJ, Millard WJ, Arendash GW, Meyer EM. The effects of aging and nucleus basalis lesions on neuropeptide Y (NPY) levels and its encoding m RNA in the rat. *Prog 19th Annual Meeting, Society for Neuroscience*. pg 839 (1989).
50. Masters BA, Pruyers CR, Millard WJ, Meyer EM, Poulakos JJ. Pre-proneuro-peptide Y mRNA expression in glial cell cultures of the neonate but not 21 day old rat brain. *Central and Peripheral Significance of NPY and its Related Peptides, NY Acad Sci*, pg 42 (1990).
51. Masters BA, Pruyers CR, Millard WJ, Poulakos JJ. Pre-pro neuropeptide Y mRNA expression in cultured glial cells of the rat. *J Cell Biochem Suppl* 14F: pg 44 (1990).
52. Millard WJ, Layden M, Appelstein A, Romano T, Simpkins JW. Alteration in the growth hormone and prolactin response to morphine during the steroid-induced LH surge. *Prog 72nd Annual Meeting, Endocrine Society*. pg 317 (1990).
53. Cugini Jr CD, Millard WJ, Leidy Jr JW. Effects of forskolin, phorbol ester, dibutyryl cAMP and calcium ionophore on release of growth hormone-releasing hormone and somatostatin from perfused rat hypothalamic fragments. *Prog 72nd Annual Meeting, Endocrine Society*. pg 54 (1990).
54. Nash MS, Street AF, Titta AE, Marcillo AE, Millard WJ. Somatotropin secretion during electrically stimulated exercise in human quadriplegics. *Am Phys Therap Assoc*. pg (1991)
55. Singh M, Millard WJ, Simpkins JW. Ovarian steroids modulate the effects of opiates on prolactin secretion in the rat. *Prog 73rd Annual Meeting, Endocrine Society*. pg 212 (1991).
56. Coleman-Hardee M, Peris J, Millard WJ. Cocaine *in utero* enhances striatal dopamine release in adult rats. *Prog 21st Annual Meeting, Society for Neuroscience*. pg 579 (1991).
57. Prieto EE, Romano TM, Millard WJ. Anterior pituitary function in adult rats exposed *in utero* to cocaine. *Prog 74th Annual Meeting, Endocrine Society*. pg 432 (1992).
58. Leidy Jr JW, Romano TM, Millard WJ. Developmental changes of the growth hormone axis in lean and obese Zucker male and female rats. *Prog 74th Annual Meeting, Endocrine Society*. pg 197 (1992).
59. Meyer EM, deFiebre CM, Notabartolo D, Millard WJ, Wu P. Use of reconstituted sendi viral envelopes to deliver NPY-containing adeno-associated virus vector to neuroblastoma and brain cells in culture and *in vivo*. *Southeast Nerve-Net Meetings* Cedar Key, FL (1993).

60. Millard WJ, Simpson ET, Scarpace PJ. The effects of chronic exercise on anterior pituitary function in aged female rats. *Prog 75th Annual Meeting, Endocrine Society*. pg 367 (1993).
61. Singh M, Meyer EM, Huang FS, Millard WJ, Simpkins JW. Ovariectomy reduces ChAT activity and NGF mRNA levels in the frontal cortex and hippocampus of the female Sprague-Dawley rat. *Prog 23rd Annual Meeting, Society for Neuroscience*. pg 1254 (1993).
62. Wu P, Millard WJ, Grouzmann E, Bonell MA, Gao Y, King M, Meyer EM. Use of adeno-associated virus vector to express exogenous neuropeptide Y in neural cells. *Prog 23rd Annual Meeting, Society for Neuroscience*. pg 391 (1993).
63. Meyer EM, Wu P, de Fiebre CM, Notabartolo D, Bonell M, King M, Millard WJ. Expression of an NPY cDNA-containing adenoassociated virus vector in brain and neuroblastoma cells after Sendai virosomal infusion. *Prog 23rd Annual Meeting, Society for Neuroscience*. pg 391 (1993).
64. Leung KC, Millard WJ, Peters E, Markus I, Barnard R, Baumbach WR, Ho KKY. Measurement of GH binding protein in the rat by a ligand immunofunctional assay. *Prog 76th Annual Meeting, Endocrine Society*. pg 609 (1994).
65. Borst SE, Simpson E, Mudrey A, Millard WJ. Effect of chronic exercise training on circulating insulin-like growth factor-I in senescent rats. *Prog 76th Annual Meeting, Endocrine Society*. pg 296 (1994).
66. Simpkins JW, Millard WJ. Mechanism of chronic LH suppression by a brain targeted estradiol-chemical delivery system (E2-CDS). *Prog 24th Annual Meeting, Society for Neuroscience*. pg 92 (1994).
67. Borst SE, Simpson E, Millard WJ. The BN/F344 Rat as a model of growth hormone insufficiency in senescence. *FASEB Journal* 9:A181 (1995).
68. Millard WJ, Simpson ET, Leung LC, Peters E, Ho KKY. Sex dependent differences in GH trough values are not the result of GH binding protein effects on the rat GH radioimmunoassay. *Prog 77th Annual Meeting, Endocrine Society*. pg 493 (1995).
69. Leidy Jr JW, Daniels KL, Millard WJ. Solid phase radioimmunoassay for somatostatin in unextracted rat plasma. *Prog 77th Annual Meeting, Endocrine Society*. pg 495 (1995).
70. Wang S, Millard WJ, Meyer EM. Adeno-associated virus (AAV) - mediated NGF gene-transfer into PC12 cells and rat brain. *Prog 25th Annual Meeting, Society for Neuroscience*. pg 37 (1995).
71. Dawson Jr. R, Millard WJ, Liu SC, Eppler B, Pellemounter MA. Reduced sensitivity of monosodium glutamate (MSG)-lesioned rats to exogenous leptin. *Prog 26th Annual Meeting, Society for Neuroscience*. pg 846 (1996).
72. Zhang YO, Day AL, Shi J, Rajakumar G, Millard WJ, Simpkins JW. Focal cerebral ischemic model using middle cerebral artery occlusion in ovariectomized rats. *Prog 26th Annual Meeting, Society for Neuroscience*. pg 1668 (1996).
73. Ulrich LJ, Blake KR, Winkles AC, Millard WJ, Simpson ET, Powers SK, Dodd SL, Brazeau GA. Effects of cocaine and exercise on skeletal muscle lipid peroxidation. *Pharmaceutical Research* 13:S491 (1996).
74. Martin RL, Eppler B, Millard WJ, Dawson RD. The effects of monosodium glutamate (MSG) and leptin treatment on brain peptide and catecholamine levels in Sprague Dawley rats. *Prog 27th Annual Meeting, Society for Neuroscience*. pg 145 (1997).
75. Martin RL, Dawson Jr. R, Millard WJ. Leptin fails to reduce food intake and body weight in rats fed a high fat diet. *Prog 28th Annual Meeting, Society for Neuroscience*. pg 450 (1998).
76. Li Y, Davis MI, He Y-J, Smith N, Grimes JR, Millard WJ, Heaton MB, King MA, Meyer EM. Nicotinic receptor mediated protection against ethanol-induced cytotoxicity. *Prog 28th Annual Meeting, Society for Neuroscience*. pg 1342 (1998).
77. Meyer EM, Li Y, Millard WJ, He Y-J, Papke RL. Neuroprotection, neurotoxicity and selective alpha7 nicotinic receptor activation. *Prog 28th Annual Meeting, Society for Neuroscience*. pg 831 (1998).
78. Monck EK, Panickar KS, Green PS, Gridley KE, Millard WJ, Simpkins JW. Effects of calcium depletion on basal and forskolin stimulated cyclic AMP response element binding protein phosphorylation in HT-22 and SK-N-SH cells. *Prog 28th Annual Meeting, Society for Neuroscience*. pg 865 (1998).
79. Yang SH, Shi J, He Y-J, Lucas TH, Millard WJ, Day AL, Simpkins JW. Estradiol exerts neuroprotective effect when administered after ischemic insult. *Prog 29th Annual Meeting, Society for Neuroscience*. pg 1848 (1999).
80. Martin RL, Perez EJ, He Y-J, Millard WJ. A test of leptin resistance in male Long-Evans rats. *Prog 29th Annual Meeting, Society for Neuroscience*. pg 620 (1999).
81. Kranz H, Thomas M, Napaporn J, Martin RL, Millard W, Brazeau GA, Bodmeier R. Myotoxicity studies of injectable biodegradable in situ forming drug delivery systems. *Annual Meeting American Association of Pharmaceutical Scientists* 1(4): S-479 (1999).
82. Li Y, Meyer EM, Millard WJ, He YJ, King MA. Mitochondrial dysfunction and ethanol neurotoxicity. *23rd Annual Meeting Research Society on Alcoholism*. 24(5) pg 66A (2000).

83. Yang S-H, He Z, Wu SS, He Y-J, Cutright J, Millard WJ, Day AJ, Simpkins JW. 17 β -estradiol can reduce secondary ischemic damage and mortality of subarachnoid hemorrhage. *Prog 30th Annual Meeting, Society for Neuroscience*. pg 780 (2000).
84. Li Y, Meyer EM, Millard WJ, He Y-J, King MA. The selective $\alpha 7$ nicotinic agonist DMXB counteracts the ethanol-induced release of mitochondrial cytochrome C. *Prog 30th Annual Meeting, Society for Neuroscience*. pg 1404 (2000).
85. Wu D, Gu W, Millard W, He Y, Lian W. Molecular cloning and characterization of human affinity choline transporter. *Prog 30th Annual Meeting, Society for Neuroscience*. pg 2142 (2000).
86. Bowles TM, Levin GM, Langae TY, Tan JY, Yarandi HN, Johnson JA, Millard WJ. Assessment of Serotonin Type 1A (5-HT_{1a}) Receptor genotype in a normal versus a depressed population and the relationship to predictability of antidepressant responsiveness. *American College of Clinical Pharmacy, 2003 Annual Meeting*. pg 34 (2003).
87. Shaw AM, Irani BG, Haskell-Luevano C, Millard WJ. Involvement of the melanocortin 3 and 4 receptors in ghrelin-induced food intake. *Prog. 33rd Annual Meeting, Society for Neuroscience*. Program # 283:17 (2003).
88. Shaw AM, Haskell-Luevano C, Millard WJ. Characterization of the growth hormone secretory axis in melanocortin 3 and 4 receptor knockout mice. *Prog. 86th Annual Meeting, Endocrine Society*. pg 315 (2004).
89. Haskell-Luevano C, Joseph C, Xiang Z, Scott J, Wilson K, Millard W, Edison A, Wilczynski A. Putative AGRP-MC4R Interactions for Drug Design. *Biology of the AGRP-Melanocortin System* pg 20 (2005).

Revised and updated:8/20/2008

Manuscripts submitted for publication: